Oscar Tahuahua: 6 Month Adjuvant Chemotherapy in pT4N0 Colon Cancer
Oscar Tahuahua, Medical Oncology Fellow at the National Cancer Institute of Mexico, shared a recent article by Valentina Daprà et al, on X, adding:
“Real-world study (n=390).
6 month adjuvant chemotherapy in pT4N0 colon cancer increased 3y OS to 98% vs 62% without; RFS: 78% vs 54%.
Oxaliplatin-based doublets cut death (HR 0.21) and recurrence (HR 0.48). MSI (25%) had no impact.
R0 resection in 97%.”
Title: Prognostic impact and clinical management of pT4N0 colon cancer: data from a large, multicenter, international, real-world dataset
Authors: V. Daprà, A. Gandini, F. Schietroma, D. Rossini, A. Boccaccino, G. Caira, M.A. Calegari, F. Zoratto, M. Costantini, V. Formica, M. Rofei, G. Mauri, E. Bonazzina, S. Siena, M.L. Iaia, C. Signorelli, L. Antonuzzo, S. Tamberi, C. Foppa, A. Spinelli, G. Tortora, A. Santoro, J. Taieb, A. Puccini, L. Salvatore
Read the Full Article on ESMO OPEN
More posts featuring Oscar Tahuahua.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023